Search results
Results from the WOW.Com Content Network
In 1961, Janssen Pharmaceuticals was purchased by New Jersey–based American corporation Johnson & Johnson, and became part of Johnson & Johnson Pharmaceutical Research and Development (J&J PRD), now renamed to Janssen Research and Development (JRD), which conducts research and development activities related to a wide range of human medical ...
In 2016, J&J was ordered to pay $72 million in damages to the family of Jacqueline Fox, a 62-year-old woman who died of ovarian cancer in 2015. The company said it would appeal. [186] A year later, over 1,000 U.S. women had sued J&J for covering up the possible cancer risk from its Baby Powder product.
In September 2016, pharmaceutical and medical device company Johnson & Johnson announced they were buying Abbott Medical Optics for $4.3 billion. [13] On February 27, 2017, Abbott Medical Optics changed its name to Johnson & Johnson Vision following its $4.3 billion acquisition by Johnson & Johnson. [14] In 2017, JJV acquired TearScience. [15]
It's also had success more broadly, getting nearly half of its workforce to use the company’s internal learning platform, J&J Learn. Meanwhile, employees using J&J's digital boot camp—courses ...
J&JPRD was created in 2001 through the merging of various research organizations including McNeil Pharmaceuticals, Janssen Research Foundation, Three Dimensional Pharmaceuticals, and the R. W. Johnson Pharmaceutical Research Institute.
A study performed by Johnson & Johnson (J&J) indicated that wellness programs saved organizations an estimated $250 million on health care costs between 2002 and 2008. Workplace wellness interventions performed on high-risk cardiovascular disease employees indicated that at the end of a six-month trial, 57% were reduced to a low-risk status.
Johnson & Johnson has agreed to pay $700 million to settle an investigation by 42 U.S. states and Washington, D.C. into its marketing of baby powder and other talc-based products blamed for ...
By Steven Brill Letter From the Editors Backstage at Johnson & Johnson. On May 20, about 100 stock analysts gathered in the ballroom of the Hyatt Regency Hotel in New Brunswick, New Jersey, to hear good news from top executives at Johnson & Johnson: The company had 10 new drugs in the pipeline that might achieve more than a billion dollars in annual sales.